Financings in Brief: Medical Device Technologies Inc.
This article was originally published in The Gray Sheet
Executive Summary
Medical Device Technologies Inc.: Enters a "firm commitment" agreement with First Allied Securities to underwrite 1.1 mil. shares of "cumulative, convertible, non-participating preferred stock, with a 6% dividend" to be sold for $5 per share. The San Diego-based company expects to receive proceeds of $5.3 mil. from the offering, which is slated to close by Dec. 1. Medical Device Technologies says it will use the proceeds to "continue development, marketing and sales" of its three medical products: the Personal Alarm System for "monitoring breakdown of infection barriers between patient and caregiver"; the Cell Recovery System for non-invasive endoscopic cell recovery and diagnosis; and the Intra-Cranial Measurement System for non-invasive determination of cranial pressure...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.